ArriVent BioPharma (AVBP)

ArriVent BioPharma (AVBP) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

Trial setback weighs on ArriVent shares

ArriVent shares slipped 0.6% today while the S&P 500 and Nasdaq 100 advanced. The recent focus remains on a failed lung cancer trial, even as the company reports progress in other drug studies and continues enrollment in a pivotal trial.

Published 2026-11-19 15:01:38 UTC.